昊海生物科技(06826.HK)擬將4552.22萬元超募資金用於投資建華生物奉賢基地項目
格隆匯5月14日丨昊海生物科技(06826.HK)公佈,公司擬使用剩餘超募資金,以及變更前次已獲批用作永久補充流動資金的超募資金,共計人民幣4,552.22萬元(含利息),用於投資建華生物奉賢基地一期建設項目("建華生物奉賢基地項目")。
建華生物奉賢基地項目計劃總投資額約為人民幣18,500.21萬元,其實施主體為公司全資附屬公司建華生物。建華生物奉賢基地項目系建設建華生物新廠房和生產線,以應對建華生物現有租賃物業因政府規劃而被要求拆遷的風險。截至公告日期,建華生物奉賢基地項目處於建設施工階段,已累計投入資金約為人民幣5,271.24萬元。除擬投入的超募資金以外,其他所需投資資金由集團自籌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.